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BACKGROUND: In March 2008, the National Institute for Health and 
Care Excellence recommended stopping antibiotic prophylaxis (AP) for 
those at risk of infective endocarditis (IE) undergoing dental procedures 
in the United Kingdom, citing a lack of evidence of efficacy and cost-
effectiveness. We have performed a new economic evaluation of AP on the 
basis of contemporary estimates of efficacy, adverse events, and resource 
implications.
METHODS: A decision analytic cost-effectiveness model was used. Health 
service costs and benefits (measured as quality-adjusted life-years) were 
estimated. Rates of IE before and after the National Institute for Health and 
Care Excellence guidance were available to estimate prophylactic efficacy. 
AP adverse event rates were derived from recent UK data, and resource 
implications were based on English Hospital Episode Statistics.
RESULTS: AP was less costly and more effective than no AP for all 
patients at risk of IE. The results are sensitive to AP efficacy, but efficacy 
would have to be substantially lower for AP not to be cost-effective. AP 
was even more cost-effective in patients at high risk of IE. Only a marginal 
reduction in annual IE rates (1.44 cases in high-risk and 33 cases in all 
at-risk patients) would be required for AP to be considered cost-effective 
at £20 000 ($26 600) per quality-adjusted life-year. Annual cost savings of 
£5.5 to £8.2 million ($7.3–$10.9 million) and health gains >2600 quality-
adjusted life-years could be achieved from reinstating AP in England.
CONCLUSIONS: AP is cost-effective for preventing IE, particularly in those 
at high risk. These findings support the cost-effectiveness of guidelines 
recommending AP use in high-risk individuals.
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antibiotic prophylaxis (AP) is a widely used preven-tion measure for those at risk of developing infec-tive endocarditis (IE). Following the suggestion that 
bacteremia secondary to invasive dental procedures might 
cause IE,1 the American Heart Association’s Committee on 
Prevention of Rheumatic Fever and Bacterial Endocarditis 
was the first to recommend that individuals at increased 
risk of IE should be given antibiotic prophylaxis (AP) before 
invasive dental procedures some 60 years ago.2 Over 
time, the American Heart Association and other interna-
tional guideline committees have gradually restricted AP 
use, moving to single-dose AP strategies and restricting 
the types of patients for whom AP is recommended.3,4 In 
2008, this culminated with the National Institute for Health 
and Care Excellence (NICE) recommending that the use of 
AP to prevent IE should cease in the United Kingdom.5 This 
recommendation was confirmed in a recent review of the 
NICE guidelines6 but is in contrast with current European,7 
North American,4 and other international guidelines that 
recommend AP for high-risk individuals undergoing invasive 
dental procedures.
A recent interrupted time series study found that AP 
prescribing in England fell sharply after the 2008 NICE 
guidance with a significant increase in the incidence of 
IE. By March 2013, it was estimated that there were 
34.9 (95% confidence interval, 7.9–61.9) more cases 
of IE per month than would have been expected from 
the previous trend.8 This increase was statistically sig-
nificant both for those at high risk (previous history of IE, 
prosthetic heart valve, valve repaired with prosthetic ma-
terial, unrepaired cyanotic congenital heart disease, or 
some repaired congenital heart defects) and moderate 
risk (native valve disease, unrepaired congenital heart 
valve anomalies, or previous rheumatic fever) of IE. This 
study provides unique evidence for evaluating the cost-
effectiveness of AP, because the United Kingdom is the 
only country to have transitioned from recommending 
AP for those at high risk or moderate risk of IE to rec-
ommending its complete cessation. Another recent UK 
study demonstrated that the incidence of adverse drug 
reactions associated with AP was much lower than previ-
ously estimated.9
This article estimates the cost-effectiveness of AP 
(single-dose amoxicillin or clindamycin for those allergic 
to penicillin) in patients at risk of IE by using (1) recent 
estimates of the effect of AP on IE in the English popula-
tion,8 (2) rates of AP adverse drug reactions,9 and (3) 
estimates for the probability of developing IE after dental 
procedures derived from French data10 as the foundation 
for analysis of cost and health benefits.
MethODs
comparators and Patient Population
The cost-effectiveness of the AP regimen that was in use in 
the United Kingdom before the 2008 NICE guidelines (a single 
3-g oral dose of amoxicillin or a single 600-mg oral dose of 
clindamycin for those allergic to penicillin or who had received 
amoxicillin in the previous month) for all at risk individuals (ie, 
those at moderate risk or high risk of IE) was compared with 
a strategy of no AP (as per the NICE guidelines5,6). We also 
compared no AP with a strategy restricting AP to just those 
at high risk of IE (as per the European7 and North American4 
guidelines). English National Health Service costs were esti-
mated and health effects measured in quality-adjusted life-
years (QALYs).
Model structure
A decision model, based on the decision model used by NICE 
for the health-economic analysis performed to inform the 
2008 guidelines,5 was constructed to estimate differences in 
costs and health benefits accruing from the short-term con-
sequences of the decision to administer AP, or not, and the 
longer-term sequelae of AP and IE (Figure). AP-related adverse 
events and IE may be fatal or lead to differences in the prob-
ability of a patient being otherwise healthy, requiring valve 
replacement surgery or experiencing congestive heart failure 
(CHF). These longer-term impacts were captured by using a 
state transition model, with 1-year cycle periods and a life-
time (50 years) time horizon. We used Treeage Pro software 
(https://www.treeage.com) and the Sheffield Accelerated 
Value of Information Tool (http://savi.shef.ac.uk/SAVI/).
clinical Perspective
What is new?
•	This study uses recent data to evaluate the cost-
effectiveness of antibiotic prophylaxis (AP) in pre-
venting infective endocarditis (IE).
•	 It demonstrates that AP before invasive dental pro-
cedures for those at moderate or high risk of IE is 
very cost-effective, in fact, cost saving.
•	Cost-effectiveness is even greater when AP is con-
fined to those at high risk of IE.
•	 For high-risk individuals, AP is cost-effective even if 
it only prevents 1.44 cases of IE per year.
What are the clinical implications?
•	 If AP was reinstated in England for those at moder-
ate or high risk of IE, it could save £5.5 to £8.2 
million ($7.3–$10.9 million; €6.6–€9.8 million) and 
result in health gains >2600 quality-adjusted life-
years per year.
•	AP is even more cost-effective for those at high risk 
of IE. Restricting AP to those at high risk would result 
in cost savings of £4.0 million ($5.32 million; €4.8 
million) and health gains of >1070 quality-adjusted 
life-years per year in England because of the smaller 
number of individuals at high risk.
•	These findings support the cost-effectiveness of 
guidelines recommending AP use, in particular, in 
high-risk individuals.
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Parameter Values
Data used to calculate the probability of IE after a high-risk (inva-
sive) dental procedure were based on previous definitions and 
estimates of the risk of adults with predisposing cardiac condi-
tions developing IE.10 The number of IE hospital admissions 
(International Classification of Diseases, 10th Revision code 
I33.0) was obtained from Hospital Episode statistics (HES; 
http://www.hscic.gov.uk/hes)11 and population data from the 
Office of National Statistics.12 A more detailed explanation of 
the calculations and values is provided in the online-only Data 
Supplement Methods and online-only Data Supplement Tables 
I and II).
Probability of ie Following a high-risk Dental 
Procedure
The probability of IE after a high-risk dental procedure was 
based on analysis of recent English data8 that estimated that 
reduced use of AP was associated with 34.9 (95% confidence 
interval, 7.9–61.9) additional IE cases per month.
The incidence of IE with AP use was derived from 2007, 
the year immediately before the introduction of NICE guidance 
(1486 cases, 28.91 per million). Table 1 reports parameter 
estimates required to translate this incidence into an estimate 
of the probability of IE. All other probabilities are shown in 
Table 2. Duval et al10 provided data on the proportion of IE 
cases associated with a predisposing cardiac condition, the 
proportion associated with a high-risk dental procedure, the 
mean number of high-risk dental procedures per year in those 
with a predisposing cardiac condition, and the prevalence of a 
predisposing cardiac condition, resulting in an estimated prob-
ability of IE of 17.98 per million high-risk dental procedures 
where routine AP would be provided.
The higher estimated annual incidence of IE in the absence 
of AP leads to an estimated probability of IE of 1785.13 cases 
per million in the high-risk group and 204.33 cases per million 
dental procedures in the all-at-risk group.
Mortality From ie
All patients were tracked for mortality within 1 year of IE diag-
nosis (International Classification of Diseases, 10th Revision 
code I33.0) using HES.11 Deaths in the community secondary 
to IE were not included because HES only records in-hospital 
mortality, resulting in a small underestimate of IE-related mor-
tality, a limitation of this data set.
Fatal and nonfatal reactions to aP
NHS Business Service Authority prescribing data were cross-
referenced with adverse drug reaction data for prescriptions 
Figure. illustration of the deci-
sion model used for the analysis. 
Key: Blue represents initial decision 
tree. Red represents subsequent 
health state transitions. Solid arrows 
are feasible pathways. Dashed arrows 
represent patient pathways from the 
decision tree to Markov models (ie, all 
living patients begin in either the well 
or valve surgery states).
 by guest on A
pril 27, 2017
http://circ.ahajournals.org/
D
ow
nloaded from
 
Cost-Effectiveness of Endocarditis Prophylaxis 
Circulation. 2016;134:1568–1578. DOI: 10.1161/CIRCULATIONAHA.116.022047 November 15, 2016
ORIGINAL RESEARCH 
ARTICLE
1571
of standard AP (single oral dose amoxicillin 3 g or clindamycin 
600 mg) from the Medicine and Health Products Regulatory 
Agency Yellow Card reporting scheme.9 The fatal and nonfatal 
adverse drug reaction rates per million prescriptions were 0 
and 22.6, and 12.6 and 149.1 for amoxicillin and clindamycin, 
respectively.9
long-term survival and Outcomes
Age-adjusted, all-cause mortality was estimated by using Office 
of National Statistics Population Prediction statistics for 2012 
to 2013.12 Mortality risk for patients that survive valve surgery 
or develop CHF (International Classification of Diseases, 10th 
Revision code I50) was estimated by using published prosthetic 
valve endocarditis registry data.13 One, 5, and 10 year survival 
in this cohort was 67.1%, 55%, and 37.6%, respectively, and 
used to estimate a Weibull survival function.5 Mortality after 
valve replacement surgery was estimated using HES data 
for patients admitted for valve replacement surgery (OPCS-4 
Classification of Interventions and Procedures version 4 codes: 
K25.1–K25.4, K26.1–K26.4, K27.1–K27.4, K28.1–K28.4, or 
K29.1–K29.4) and discharged as dead within the same spell 
for the year 2012.
The annual probability of IE survivors developing CHF over 
5-year follow-up was estimated from HES. Of the 19 804 
patients with IE and reliable 5-year follow-up data, the numbers 
diagnosed with CHF were 2152, 387, 292, 170, and 157 
in years 1 to 5, respectively. The subsequent probability of 
developing CHF until the end of the model’s time horizon was 
assumed to be constant after year 5. Recent studies show that 
40% to 50% of patients now undergo valve replacement sur-
gery as part of their initial IE treatment,14–16 and, for this transi-
tion probability, we adopted a conservative 40% estimate. The 
annual probability of IE survivors needing valve surgery after the 
initial admission was estimated by using HES. Of the 19 804 
patients diagnosed with IE and followed for 5 years, 1278 
required valve replacement surgery during the first year after 
their initial IE treatment, and 329, 158, 75, and 74 required 
valve replacement surgery in years 2 to 5, respectively. The 
subsequent probability of needing valve surgery is assumed to 
remain at 74 cases per year through to year 9, before falling 
to 17 cases per year until the end of the model’s time horizon.
table 1. Data Used to estimate the Probability of ie after a high-risk (invasive) Dental Procedure
Variable Mean Population (n) Occurrence (r) Distribution
All-at-risk group
  a. Incidence of IE (per million people per annum) 28.9 51.4 m12 148611 Beta
  b. Incident cases that would have occurred in at-risk patients* 0.521 137010 71410 Beta
  c. IE cases attributed to dental procedures in at-risk group 0.052 71410 3710 Beta
  d. Number of dental procedures/patient/y for at-risk patients* 1.32 1 287 29610 1 704 19510 –
  e. Prevalence of at-risk patients 3.30% 39 000 00010 1 287 29610 Beta
  f. Increase in cases of IE per month as a result of AP cessation† 34.98 – – Gamma
  Estimated number of dental procedures per year for at-risk patients‡ 2.24 m – – –
  Probability of IE after a dental procedure with AP (per million people)§ 17.87 – – –
  Probability of IE after a dental procedure without AP (per million people)‖ 204.33 – – –
High-risk group
  Incidence of IE (per million people per annum) 28.9 51.4 m12 148611 Beta
  Incident cases that would have occurred in high-risk patients* 0.288 148611 42811 Beta
  IE cases attributed to dental procedures in high-risk patients 0.031 22410 710 Beta
  Number of dental procedures/patient/y in high-risk patients* 0.33 228 57010 75 40910 –
  Prevalence of high-risk patients 0.59 39 000 00010 228 57010 Beta
  Increase in cases of IE per month as a result of AP cessation# 13.78 – – Gamma
  Estimated number of dental procedures per year for high-risk patients 0.1 m – – –
  Probability of IE after a dental procedure with AP (per million people) 134.58 – – –
  Probability of IE after a dental procedure without AP (per million people) 1785.13 – – –
AP indicates antibiotic prophylaxis; and IE, infective endocarditis.
*At risk of IE patients are mainly defined as those patients with a predisposing cardiac condition, although at risk has been defined by Duval et al10 and 
Dayer et al8 from which these data were obtained.
†Mean extra cases per month8: 34.9 cases (95% confidence interval,8 7.9–61.9; standard errors, 13.78); mean extra cases per year: 418.8 cases.
‡Calculated as (g.d.e) where (g) is the population of England for the year 2007: 51.4 million.12
§Calculated as (a.b.c)/(d.e).
‖Calculated as ((a+f).b.c)/(d.e).
#Mean extra cases per month8: 13.7 cases (95% confidence interval,8 –3.29 to 30.64; standard errors: 8.66); mean extra cases per year: 164.0 cases.
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table 2. summary of transitional Probabilities for adverse health states, Mortality, and adverse side effects
Parameter Base case r (Occurrences) n (Population) comments
Adverse health states
  Developing congestive heart failure after 
IE*
1–5 y prognosis: 
0.109; 0.02; 0.015; 
0.009; 0.008
1–5 y No. cases11: 
2,152; 387; 292; 170; 
157
19 804†11
Probability assumed constant 
after the fifth year.
  Developing congestive heart failure  
(non-IE cases) *
0.007 360 47111 53,500,000‡12
–
  Valve replacement during or immediately 
after IE*
0.400 7922 19 804†11
Number of occurrences  
(7922) based on assumed 40% 
of patients requiring immediate 
valve replacement surgery in a 
population of 19 804 people.14–16
  Valve replacement/repair, years 1–10  
(IE cases)*
1–5 y prognosis: 
0.065; 0.017; 
0.008; 0.004; 
0.004
1–5 y No. cases11: 
1278; 329; 158; 75; 
74
19 804†11
Number of events does  
not include those patients 
included in the valve 
replacement during or 
immediately after IE arm; 
probability assumed constant 
after the fifth year until year 9, 
before falling to 17 cases/y.
  Valve replacement/repair (non-IE cases)* <0.001 234011 53 500 000‡12 –
  Valve replacement/repair, after 10 y  
(IE cases)*
0.001 1711 19 804†11
–
Mortality
  Overall mortality risk by age
Office of National Statistics Population Prediction statistics  
2012/1312
Office of National Statistics 
Population Prediction  
statistics for mortality in the 
years 2012/13 for 5 age groups: 
50–59; 60–69; 70–79; 80–89; 
90+.
  Mortality from IE: general
0.108 23211 2145§11
Death from AE within the first 
year (calculated from Hospital 
Episode Statistics data for the 
year 2012).
  Death from valve surgery
0.040 6411 2340‖11
Discharged as dead within the 
same spell as valve surgery 
(calculated from Hospital Episode 
Statistics for the year 2012).
  Death for patients with a successful valve 
replacement Weibull function
(lambda = 0.144; gamma = 0.368)5
Weibull function as used in 
the NICE prophylaxis against 
infective endocarditis model for 
the 2008 guidance
  Death for all patients developing 
congestive heart failure Weibull function as per patients with a successful valve  
replacement/repair5
Weibull function as used in 
the NICE prophylaxis against 
infective endocarditis model for 
the 2008 guidance
Adverse side effects
  Nonfatal side effect to amoxicillin
22.62 per million9 – –
No distinction on type of nonfatal 
side effect.
(Continued )
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health-related Quality of life (Utility) Weights
Mean health state utility values, required for estimating QALYs, 
and associated standard deviations were taken from different 
sources that are described in this section. UK population age 
norms17 were used to adjust and parameterize all utility values 
for the 5 health states in the model.
Adults in the well state were considered to be equivalent 
to patients with a New York Heart Association class 1 (ie, 
people with cardiac disease but no symptoms or limitations 
in function).18 Patients in the needing-valve-surgery state 
were assumed to correspond to New York Heart Association 
class III/IV.19,20 We assumed the utility value of 0.525 would 
be relevant only for 6 months before the same value as the 
Successful-valve-surgery state utility value would be relevant. 
Successful valve surgery was estimated by using data for 
New York Heart Association class I/II patients after valve 
replacement, with a utility value of 0·855.18,21,22 CHF was esti-
mated as the weighted average of those not hospitalized20 
and those hospitalized (New York Heart Association class 
III)20,23 based on 0.53 hospitalizations per year24 of 7.53 days 
duration.25 The health state and age utility values used are 
shown in Table 3.
costs
National sources for unit costs were used. The cost of amoxi-
cillin (£2.28 [$3.03, €2.74]) and clindamycin (£1.14 [$1.52, 
€1.37]) were obtained from the British National Formulary 
(Number 65) for 2013.26 Secondary care costs were estimated 
using 2012 to 2013 National Reference costs.25,27 General 
practice consultation costs for AP adverse events were from 
Curtis.27 Exchange rates shown between UK£, US$, and the 
Euro € were calculated on the July 1, 2016 using the midmar-
ket rate (£1=$1.33=€1.20).
Patients with CHF or previous valve surgery were assumed 
to require 2 cardiology outpatient visits per year. Those with 
CHF were assumed to require treatment with angiotensin-con-
verting enzyme/angiotensin II inhibitors, β-blockers, digoxin, 
and high-dose loop diuretics at typical daily doses.5,28 A sum-
mary of these unit costs is provided in Table 4.
All costs were discounted by 3.5% as suggested by 
NICE 2013 technology appraisal guidelines.29 A range of 
sensitivity analyses was performed, including probabilistic 
sensitivity analysis, to reflect different aspects of uncertainty 
in the evidence.
statistical analysis
An initial decision tree model leading to a state transition 
model was used to estimate the cost per QALY gained of AP 
versus no AP over a time horizon of 50 years. One-way and 
probability sensitivity analysis and expected value of perfect 
information (EVPI) analysis were also conducted. We used 
Treeage Pro software (https://www.treeage.com) to construct 
the decision tree and state transition model and the Sheffield 
Accelerated Value of Information Tool (http://savi.shef.ac.uk/
SAVI/) for the EVPI analysis.
This analysis was performed in compliance with the 
Consolidated Health Economic Evaluation Reporting Standard 
(CHEERS) guidelines for the reporting of health economic anal-
yses.30 Ethics approval was not required for this study because 
it was confined to analysis of publicly available data containing 
no identifiable patient information.
  Nonfatal side effect to clindamycin
149.1 per million9 – –
No distinction on type of nonfatal 
side effect.
  Fatal side effect to amoxicillin
0 per million9 – –
No distinction on type of fatal 
side effect.
  Fatal side effect to clindamycin
12.6 per million9 – –
No distinction on type of fatal 
side effect.
IE, infective endocarditis; and NICE, National Institute for Health and Care Excellence.
* Diagnosis codes for congestive heart failure and valve replacement presented in Methods.
†Number of patients diagnosed with IE whose Hospital Episode Statistics data could be traced for up to 5 years after diagnosis.11
‡Population of England in 2012.12
§Number of cases of IE in 2012.11
‖Number of people who had valve surgery in 2012.11
table 3. Utility Values, by health state and age 
group
group Mean
standard 
Deviation Distribution
UK population norms by age, y17
  50–54 0.85 0.25 Beta
  55–64 0.80 0.26 Beta
  65–74 0.78 0.26 Beta
  75+ 0.73 0.27 Beta
Health states
  Well18 0.930 – –
  Valve replacement/repair 
needed19,20
0.525 – –
  Successful valve 
replacement18,21,22
0.855 – –
  Congestive heart failure20 0.610 – –
  Hospitalization with heart 
failure20,23
0.570 – –
table 2. continued
Parameter Base case r (Occurrences) n (Population) comments
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resUlts
In comparison with no AP, both amoxicillin and clindamy-
cin AP were associated with lower costs and better health 
outcomes (Table 5) for both high-risk and all-at-risk popu-
lations. In the all-at-risk group, there were mean cost sav-
ings of £2.47 (95% credible interval [CrI], £0.48–£6.96) 
($3.29; CrI $0.64–$9.26; €2.96, CrI €0.58–€8.35) 
per person with amoxicillin AP and £3.65 (95% CrI, 
£0.69–£8.14) ($4.86; 95% CrI, $0.92–$10.83; €4.38, 
95% CrI, €0.83–€9.77) with clindamycin AP, in compari-
son with no AP (the difference between the drugs being 
driven by the lower cost of clindamycin: £1.14 versus 
£2.28 [$1.52 versus $3.03; €1.37 versus €2.74]).26 
With an estimated 2.24 million dental procedures per 
year in this population (Table 1), AP would lead to sav-
ings of £5.5 million to £8.2 million per annum ($7.3 mil-
lion to $10.9 million; €6.6 million to €9.8 million). We 
calculated a mean health improvement of 0.0012 (95% 
CrI, 0.000–0.003) and 0.0010 (95% CrI, 0.000–0.002) 
QALYs per person for amoxicillin and clindamycin, re-
spectively (equivalent to 2687 QALYs gained per annum 
at the population level if amoxicillin AP were used for 
all-at-risk patients).
These cost savings were substantially greater in the 
high-risk group at a mean of ≈£40 ($53.2; €48.00) per 
patient (or £4.0 million [$5.3 million; €4.8 million] per 
annum in England on the basis of an estimated 100 000 
dental procedures in this population). The most effective 
strategy would be amoxicillin, leading to gains of 0.0107 
QALYs per person (or 1071 QALYs for the population) 
per annum.
sensitivity analysis
A sensitivity analysis on the effectiveness of AP was 
performed by varying the number of additional IE cases 
associated with AP withdrawal from 35 per month (base 
case) to zero (implying AP has no protective effect). For 
the all-at-risk group, amoxicillin remained cost saving un-
til the rate of IE cases avoided fell below 16.8 per month 
and cost-effective (at £20 000 [$26 600; €24 000] per 
table 4. summary of Unit costs
Mean 25% 75% sD comments
AP (per course)
  Oral amoxicillin 3 g
2.28 Fixed
3 g sachet, powdered sugar free (14 sachet 
pack=£31.94) 26
  Oral clindamycin 600 mg 1.14 Fixed 4 capsules × 150 mg dose (24 × 150 mg: £6.85) 26
Secondary care
  Hospitalization for endocarditis
5136 2604 6943 1220
Weighted average nonelective long stay cost for 
“Endocarditis with CC scores”25;
Weighted average length of stay=12.71 days25
  Hospitalization for valve surgery
10 204 8082 11712 1018
Weighted average elective long stay cost for “Single 
Cardiac Valve Procedure with CC scores”25;
Weighted average length of stay=6.61 days25
  Hospitalization for heart failure
2647 2040 3116 317
Weighted average nonelective long stay cost for 
“Heart Failure or Shock with CC scores”25;
Weighted average length of stay=7.53 days25
  Fatal anaphylaxis
375 265 447 49
Weighted average nonelective short stay cost for 
“Shock and Anaphylaxis, with CC Scores”25
  Cardiology OP visit
126 85 147 14
Consultant-led outpatient cost for “Non-Admitted 
Face to Face Attendance, Follow-up” for service 
“Cardiology”25
  Death
230 207 255 17
Ambulance service cost for “See and treat and 
convey”25
Other costs
  Annual drug cost for patients with 
heart failure
76.12 69.33 80.08 5.87
Drug type and dose as described by Fox et al28 for 
patients in NYHA class III; prices from BNF 65.26
  Nonfatal allergic reaction
37 Fixed
General practice surgery consultation  
lasting 11.7 min.27
All costs are in £. AP indicates antibiotic prophylaxis; BNF, British National Formulary; DoH, Department of Health; NYHA, New York Health Association; 
OP, Outpatient; and SD, standard deviation.
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QALY) until the rate fell below 2.76 per month (33.12 
cases per year). In the same population, use of clindamy-
cin was cost saving until the rate fell below 8·1 cases 
per month and cost-effective (at £20 000 per QALY) until 
the rate fell below 6.2 cases per month.
In the high-risk group, amoxicillin remained cost saving 
provided the number of IE cases avoided with AP use was 
>0.74 per month and cost-effective (at £20 000 per QALY) 
provided the number of IE cases avoided was >0.12 per 
month (base case estimate 13.67 extra high-risk IE cases 
per month8) or 1.44 cases per year. For clindamycin, the 
corresponding values were 0.36 and 0.27, respectively.
Value of information
Cost-effectiveness estimates are subject to uncertainty 
relating to values of the input parameters on clinical ef-
fectiveness, costs, and health outcomes. This uncertain-
ty is a genuine concern because any decision could be 
incorrect: health benefits could be lost because of invest-
ment in a treatment that is not cost-effective. The value 
of eliminating all uncertainty, such that there is no risk 
of an incorrect decision, is called the Expected Value of 
Perfect Information (EVPI),31 which provides an estimate 
of the upper bound of the cost of any additional research 
that would reduce uncertainty. For the all-at-risk popula-
tion, the EVPI is near zero (£9020 [$11 997; €10 824] for 
amoxicillin, £11 409 [$15 174; €13 691] for clindamycin 
over 10 years in England). This is because there is little 
uncertainty; AP is almost certainly cost-effective, and, 
therefore, reducing uncertainty in any of the input param-
eters would be unlikely to lead to a different conclusion. 
However, the clinical effectiveness of AP is subject to 
some uncertainty because of reliance on observational 
data and interrupted time-series analysis.8
Accordingly, we conducted an additional exploratory 
analysis in which assumptions concerning uncertainty 
around the efficacy of AP in the all-at-risk population 
were increased. The base case analysis assumes that 
withdrawal of AP led to 34.9 additional cases of IE per 
month. Therefore, a model averaging approach was used 
such that half the sample maintained this estimate and 
half used an estimate of zero (ie, AP has no effect). This 
resulted in AP (amoxicillin) being less cost saving (now 
£0.15 per person; 95% CrI, –£5.62 to £2.28 [$0.20; 
95% CrI, –$7.48 to $2.74; €0.18, 95% CrI, –€6.74 to 
€2.74]) and more effective, although less so than in the 
base case (0.00061 QALYs; 95% CrI, 0.000–0.002). The 
probability of being cost saving is 0.48, and the prob-
ability of being cost-effective (at a £20 000 threshold) 
is 0.50. In this situation, the EVPI rises to £25.3 million 
($33.7 million; €30.4 million), driven almost entirely by 
the introduced uncertainty concerning AP effectiveness.
DiscUssiOn
We recently estimated the impact of the withdrawal of AP 
on the incidence of IE in an interrupted time-series analy-
table 5. costs and effects of antibiotic Prophylaxis Versus no antibiotic Prophylaxis: Base case analysis
antibiotic 
strategy
Mean 
cost
incremental 
cost
(95% credible 
interval) Mean QalY
incremental 
QalY
(95% credible 
interval)
icer
(aP vs
no aP)
Probability 
cost-effective annual 
cost 
savings
annual 
QalY gain20k 30k
All-at-risk population, 50-y time horizon
  No AP £4082.74 – 15.9549 – – – – – –
  Amoxicillin
£4080.27
–£2.47
(–6.96 to 0.48)
15.9561
0.0012
(0.000 to 0.003)
Dominant 0.999 0.999 £5 530 290 2687
  Clindamycin
£4079.09
–£3.65
(–8.14 to  
–0.69)
15.9559
0.0010
(0.000 to 0.002)
Dominant 0.999 0.999 £8 172 292 2239
High-risk population, 50-y time horizon
No AP £4123.02 – 15.9447 – – – – – –
Amoxicillin
£4083.24
–£39.78
(–106.61 to 
–4.53)
15.9553
0.0107
(0.001 to 0.030)
Dominant 1.00 1.00 £3 981 015 1071
Clindamycin
£4082.06
–£40.96
(–108.35 to 
–6.15)
15.9551
0.0104
(0.001 to 0.029)
Dominant 1.00 1.00 £4 099 105 1041
Both AP strategies are compared with the common baseline of no AP. Estimated 2.2 million and 0.1 million dental procedures per annum in at-risk 
and high-risk populations, respectively; these figures of 2.2 million and 0.1 million and their calculation are presented in Table 1. AP indicates antibiotic 
prophylaxis; ICER, incremental cost effectiveness ratio; QALY, quality-adjusted life-year.
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sis of English data.8 This study provided unique evidence 
for evaluating the cost-effectiveness of AP, because the 
United Kingdom is the only country to have transitioned 
from the widespread use of AP to recommending its 
complete cessation. Using these figures as inputs to 
a cost-effectiveness analysis indicates that AP is likely 
to be not just cost-effective, but also cost saving. If AP 
were used in all those at risk of IE, then amoxicillin and 
clindamycin AP would result in estimated cost savings 
of £2.47 ($3.29; €2.96) and £3.65 ($4.86; €4.38) per 
patient and health gains of 0.0012 and 0.0010 QALYs, 
respectively. Overall, AP would result in an estimated 
saving of £5.5 to £8.2 million ($7.3 million to $10.9 mil-
lion; €6.6 million to €9.8 million) and a health gain of 
2687 QALYs in England per year. If AP were restricted 
to those at high risk of IE, the cost savings and health 
gain per person would be even greater at £40 ($53.20; 
€48.00) and 0.0107 QALYs. The overall benefit of us-
ing amoxicillin AP in high-risk patients would be a cost 
savings of £4.0 million ($5.3 million; €4.8 million) and a 
health gain of 1071 QALYs in England per year.
Because the recent time-series analysis was an ob-
servational study,8 we cannot be certain that the number 
of extra cases of IE identified was caused by the reduc-
tion in AP prescribing following the 2008 NICE guide-
lines.5 It is possible, therefore, that the number of IE cas-
es prevented by AP is less than the identified 34.9 per 
month. To evaluate the cost-effectiveness of AP across 
a range of scenarios we performed a sensitivity analy-
sis using a maximum effectiveness of preventing 35 
IE cases per month and a minimum of preventing zero 
cases, ie, where AP is ineffective. Using this approach, 
we demonstrated that amoxicillin AP has to prevent only 
2.76 cases per month in the all-at-risk group to be cost-
effective and 16.8 cases per month to be cost saving. 
Moreover, amoxicillin AP is even more cost-effective in 
the high-risk group where only 0.12 cases per month 
need to be prevented for it to be cost-effective and 0.74 
cases per month to be cost saving.
These data suggest that a strategy of directing AP 
at those at high risk of IE is likely to be cost-effective or 
cost saving, even at very low rates of AP clinical effec-
tiveness. This conflicts with the NICE health economic 
analysis of AP,5 which used older data on the incidence 
of adverse drug reactions after the use of parenteral 
penicillins.5 More recent data suggest that fatal anaphy-
laxis is exceedingly rare, and there have been no reports 
of fatal anaphylaxis after oral amoxicillin AP in the world 
literature.32 The incidence of adverse reactions after 
amoxicillin AP is extremely low (0 fatal, 22.62 nonfatal 
reactions per million prescriptions).9,32 Although low, re-
actions to clindamycin AP were higher than anticipated, 
suggesting that an alternative AP regimen for those al-
lergic to penicillin would be desirable.9 Our data suggest 
that AP needs only minimal clinical effectiveness to be 
cost-effective, because it is so cheap in comparison with 
the substantial cost and health implications of IE.
International guideline committees have highlighted 
the lack of evidence for the benefit of AP and called 
for randomized clinical trials (RCTs) to provide that evi-
dence.4,6,7 However, ethical issues and the high cost of 
performing an RCT have prevented such a study to date. 
Skepticism concerning noncontrolled data represents a 
genuine source of uncertainty about the cost and clinical 
effectiveness of AP that underpin any cost-effectiveness 
analysis. This uncertainty conveys a risk that the advice 
given by guideline committees is wrong. However, there 
is also a cost associated with performing the RCTs need-
ed to eliminate that uncertainty. EVPI analysis provides 
an estimate of the maximum amount it is worth spending 
to reduce that uncertainty.31 If there is genuine uncertain-
ty about whether AP is effective or not, then the value of 
an RCT becomes substantial. Exploratory analysis using 
the at-risk population of England over a 10-year period 
estimates the EVPI of amoxicillin at £25.3 million ($33.7 
million; €30.4 million). Therefore, although such a study 
may be costly, its value may well outweigh its cost.
The main limitations of this study are the lack of RCT 
data and the resulting need to use observational stud-
ies to identify the input parameters for health economic 
analysis. In particular, our data on the effectiveness of 
AP are based on the increase in IE cases and fall in 
AP prescribing that occurred after the introduction of 
the 2008 NICE guideline.8 Although this study demon-
strated a temporal association between the fall in AP 
prescribing and increasing IE incidence, it did not prove 
a causal link. Hence, we undertook a sensitivity analy-
sis to examine the cost-effectiveness of AP if the level 
of AP clinical effectiveness was less than anticipated. 
Furthermore, we used pre- and post-NICE prescribing 
figures as proxies for the use of AP even though compli-
ance is never 100%. A final limitation is that HES data 
were used to populate most transitional probability es-
timates in our model; events occurring outside the hos-
pital setting were not captured. IE is also complicated 
by a number of high-cost serious outcomes, eg, stroke 
and renal failure,14,15 that we were unable to take into 
account. Our analysis is likely, therefore, to have under-
estimated the impact of IE and cost-effectiveness of AP. 
Although our analysis is specific to England, its findings 
are likely to be broadly applicable to other advanced 
healthcare systems. However, cost-effectiveness may 
be even greater in nations with higher healthcare costs 
(eg, United States) but lower in those where healthcare 
costs are cheaper.
cOnclUsiOn
Because of the serious consequences and high costs 
associated with IE and the comparatively low costs as-
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sociated with AP, this analysis demonstrates that AP is 
likely to be very cost-effective (and even cost saving) in 
preventing IE, particularly for those at high risk, even 
when the number of prevented IE cases is very low. Our 
data suggest that European and American guidelines 
recommending AP use in high-risk individuals are likely 
to be cost-effective.
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1. Supplementary Methods 
 
Calculation for risk of IE following an (un)protected high-risk (invasive) dental 
procedure 
 
A similar method for calculating risk of IE following a dental procedure for patients 
with a predisposing cardiac condition (PCC) was incorporated in the NICE 2008 
model1, 2 and by three other studies.3-5 This calculation was: 
 
A slightly different and simpler way of presenting Equation 1 is presented as part of 
Equation 2, where people with a PCC are now defined as people “at-risk” of IE, of 
which people with PCC are the majority. The steps used to get to the point of 
estimating Equation 2 are described in this Appendix. 
 
It is information provided by Dayer, et al (2015)6 and Duval, et al (2006)5, 
supplemented with data obtained from HES and ONS7 which provides the basis for 
calculating the risk of IE following an unprotected dental procedure for this study. 
The logic for this calculation using the figures presented in Table 1 are now presented 
in Table A1 and Table A2 for four hypothetical patient groups:  
1) All-at-risk patients undergoing a protected dental procedure (AP is used), 
Table S1; 
2) All-at-risk patients undergoing an unprotected dental procedure (AP not 
used), Table S1;  
3) High-risk patients undergoing a protected dental procedure (AP is used), 
Table S2;  
4) High-risk patients undergoing an unprotected dental procedure (AP not 
used), Table S2. 
In order to describe the calculation used to estimate the risk of IE following a 
protected dental procedure, consider the calculation for the first hypothetical patient 
group (All-at-risk patients undergoing a protected dental procedure (AP is used)) 
Risk of IE following an unprotected dental procedure = 
(“Incidence of IE” multiplied by “proportion of incident cases that would have occurred with a PCC” 
multiplied by “proportion of PCC IE cases attributed to dental procedures”) divided by 
(“number of dental procedures per patient per year” multiplied by ”prevalence of PCC”) 
Equation 1: Equation to calculate the risk of IE following an unprotected dental procedure 
 
Risk of IE following an (un)protected dental procedure = 
“The risk of IE in an at-risk population per year multiplied by  
“Number of dental procedures/patient/year for at-risk patients”  
Equation 2: Alternative equation to calculate the risk of IE following an unprotected dental 
procedure 
 
 3 
using the figures presented in Table 1 (presented here in Italic font) and calculations 
presented in Table S1 (presented here in Bold font). 
Step 1 – estimate “Number of IE cases in all-at-risk group”: The “Number of IE cases 
per year” (1486) is multiplied by the “Incident cases that would have occurred for at 
risk-patients” (0.0521) which estimates the “Number of IE cases in all-at-risk group” 
(1486*0.0521 = 774.46).  
Step 2 – estimate “Number of IE cases due to dental work for all-at-risk”: The 
“Number of IE cases in all-at-risk group” (774.46) is multiplied by “IE cases 
attributed to dental procedures in at-risk group” (0.052) which estimates the “Number 
of IE cases due to dental work for all-at-risk” (774.46*0.052 = 40.13). 
Step 3 – estimate “Size of the population of all-at-risk patients”: The size of the 
population of interest (for the purpose of this analysis, “Population of England (year 
2012)”: 51.4 million people) multiplied by the “Prevalence of all-at-risk group” 
(0.033) estimates the “Size of the population of all-at-risk patients” (51.4 mil * 0.033 
= 1,696,590). 
Step 4 – estimate “Risk of IE in this all-at-risk population per year”: The “Number of 
IE cases due to dental work for all-at-risk” (40.13) multiplied by “Size of the 
population of all-at-risk patients” (1,696,590) estimates the “The risk of IE in this all-
at-risk population per year” (40.13 * 1,696,590 = 0.000024). 
Step 5 – estimate “Risk per protected dental procedure for all-at-risk” (Equation 2): 
“Risk of IE in this all-at-risk population per year” (0.000024) multiplied by “Number 
of dental procedures/patient/year for at-risk patients” (1.32) estimates “Risk per 
protected dental procedure for all-at-risk” (0.000024 * 1.32 = 0.000018) 
Step 6 – estimate “Risk per million per protected dental procedure for all-at-risk”: 
“Risk per protected dental procedure for all-at-risk” (0.000018) multiplied by one 
million people estimates “Risk per million per protected dental procedure for high-
risk” (0.000018 * 1 million people = 17.87) 
When accounting for the increase in cases of IE due to the cessation of AP 
(unprotected dental procedures), these same steps are taken; however, steps 1 and 2 
are replaced by one step which involves adding the “Yearly increase in IE due to no 
AP for all-at-risk” (418.8) to the “Number of IE cases due to dental work for all-at-
risk” before the cessation of AP (40.13), which now estimates the “Number of IE 
cases due to dental work for all-at-risk” without the use of AP (418.8 + 40.13 = 
458.93). These estimated figures are all presented in Table S1 for all-at-risk patients 
(as described in this example) and Table S2 for high-risk patients. 
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2. Supplementary Tables 
Table S1. Logic behind the risk per protected and unprotected dental procedure for all-at-risk patients calculation 
Description of estimate Estimate Calculation Description of calculation 
Protected dental procedure (AP is used) – all figures for this calculation are presented in Table 1 
Number of IE cases per year 1486 - - 
Number of IE cases in all-at-risk group 774.46 1486 * 0.0521 Number of IE cases per year *  
Incident cases that would have occurred for all-at-risk 
patients 
Number of IE cases due to dental work for all-at-risk 40.13 774.46 * 0.052 Number of IE cases in all-at-risk group * 
IE cases attributed to dental procedures in all-at-risk 
group 
    
Size of the population of all-at-risk patients 1,696,590 51.4mil * 0.033 Population of England (year 2012) * 
Prevalence of all-at-risk group 
Risk of IE in this all-at-risk population per year 0.000024 40.13 / 1,696,590 Number of IE cases due to dental work * 
Size of the population of all-at-risk patients 
    
Risk per protected dental procedure for all-at-risk 0.000018 0.000024 * 1.32 Risk of IE in this all-at-risk population per year *  
Number of dental procedures/patient/year for all-at-
risk patients 
Risk per million per protected dental procedure for 
high-risk 
17.87 0.000018 * 1mil Risk per unprotected dental procedure for all-at-risk * 
One million people 
 
Unprotected dental procedure (AP not used) – all figures for this calculation are presented in Table 1 
Monthly increase in IE due to no AP for all-at-risk 34.9 - - 
Yearly increase in IE due to no AP for all-at-risk 418.8 34.9 * 12 Monthly increase in IE due to no AP for all-at-risk * 
12 months in a year 
Number of cases due to dental work for all-at-risk 458.93 40.13 + 418.8 Number of IE cases due to dental work + 
Yearly increase in IE due to no AP for all-at-risk 
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Size of the population of all-at-risk patients 1,696,590 51.4mil * 0.033 Population of England (year 2012) * 
Prevalence of all-at-risk group 
The risk of IE in this population per year 0.000271 458.93 / 
1,696,590 
Number of cases due to dental work for all-at-risk * 
Size of the population of all-at-risk patients 
    
Risk per unprotected dental procedure for all-at-
risk 
0.000204 0.000271 * 1.32 The risk of IE in this all-at-risk population per year 
*  
Number of dental procedures/patient/year for all-at-
risk patients 
Risk per million per unprotected dental procedure for 
all-at-risk 
204.33 0·000204 * 1mil Risk per unprotected dental procedure for all-at-risk * 
One million people 
AP: Antibiotic Prophylaxis; IE: Infective Endocarditis. 
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Table S2. Logic behind the risk per protected and unprotected dental procedure for high-risk patients calculation 
Description of estimate Estimate Calculation Description of calculation 
Protected dental procedure (AP is used) – all figures for this calculation are presented in Table 1 
Number of IE cases per year 1486 - - 
Number of IE cases in high-risk group 428 1486 * 0.288 Number of IE cases per year *  
Incident cases that would have occurred for high-risk 
patients 
Number of IE cases due to dental work for high-risk 13.38 428* 0.031 Number of IE cases in high-risk group * 
IE cases attributed to dental procedures in high-risk 
group 
    
Size of the population of high-risk patients 301,244 51.4mil * 0.0059 Population of England (year 2012) * 
Prevalence of high-risk group 
The risk of IE in this population per year 0.000044 13.38 / 301,244 Number of IE cases due to dental work * 
Size of the population of high-risk patients 
    
Risk per protected dental procedure for high-risk 0.000135 0.000044 * 0.33 The risk of IE in this high-risk population per year *  
Number of dental procedures/patient/year for high-
risk patients 
Risk per million per protected dental procedure for 
high-risk 
134.58 0.000135 * 1mil Risk per protected dental procedure for high-risk * 
One million people 
 
Unprotected dental procedure (AP not used) – all figures for this calculation are presented in Table 1 
Monthly increase in IE due to no AP for high-risk 13.7 - - 
Yearly increase in IE due to no AP for high-risk 164.0 13.67 * 12 Monthly increase in IE due to no AP for high-risk * 
12 months in a year 
Number of cases due to dental work for high-risk 177.42 13.38 + 164.04 Number of IE cases due to dental work + 
Yearly increase in IE due to no AP for high-risk 
    
Size of the population of high-risk patients 301,244 51.4mil * 0.0059 Population of England (year 2012) * 
 7 
Prevalence of high-risk group 
The risk of IE in this population per year 0.000271 177.42 / 301,244 Number of cases due to dental work for high-risk * 
Size of the population of high-risk patients 
    
Risk per unprotected dental procedure for high-
risk 
0.001785 0.000271 * 0.33 The risk of IE in this high-risk population per year *  
Number of dental procedures/patient/year for high-
risk patients 
Risk per million per unprotected dental procedure for 
high-risk 
1785.13 0.001785 * 1mil Risk per unprotected dental procedure for high-risk * 
One million people 
AP: Antibiotic Prophylaxis; IE: Infective Endocarditis. 
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